

# [Study shows Abbott's TBI test could predict outcomes from brain injury](#)

written by CAP TODAY  
September 19, 2022

September 2022—Abbott announced that a study published in *Lancet Neurology* demonstrates the ability of two blood-based biomarkers to predict how a person will recover from traumatic brain injury (TBI) (Korley FK, et al. *Lancet Neurol.* 2022;21[9]:803-813).



©2026 CAP TODAY, all rights reserved.

---

# [FDA clears BioMérieux Nephrocheck test on Vidas](#)

written by CAP TODAY  
September 19, 2022

September 2022—The FDA has cleared the BioMérieux Vidas Nephrocheck assay to detect kidney stress in patients at risk of acute kidney injury.



©2026 CAP TODAY, all rights reserved.

---

# **Bio-Rad introduces quality control workbook series**

written by CAP TODAY  
September 19, 2022

September 2022—Bio-Rad Laboratories has launched the first workbook in a series that offers Professional Acknowledgement for Continuing Education credits.



©2026 CAP TODAY, all rights reserved.

---

# **Roche COVID-19 test detects, differentiates BA.2.75**

written by CAP TODAY  
September 19, 2022

September 2022—Roche and its subsidiary TIB Molbiol have developed a COVID-19 test that detects and differentiates the BA.2.75 subvariant. The VirSNiP SARS-CoV-2 Spike 147E 152R test, for research use only, targets two of the known unique mutations, K147E and W152R, in BA.2.75, which allows clear differentiation against other notable subvariants. The test is for use on the Lightcycler and Cobas z480 instruments and is available worldwide.



©2026 CAP TODAY, all rights reserved.

---

# Highs, lows of tumor mutation burden testing

written by CAP TODAY  
September 19, 2022

September 2022—It may not be the oldest story in the world, but in clinical laboratories it's an oft-told tale: Tumor meets biomarker; drug meets companion diagnostic; both meet FDA approval; clinicians meet with patients offering new hope—and those in the lab are left trying to figure out how to make it all work. That story is playing out again in the realm of measuring tumor mutational burden. In mid-2020 the FDA approved pembrolizumab as a new treatment option in adult and pediatric patients with TMB-high ( $\geq 10$  mutations/megabase) solid tumors, as determined by the FDA-approved FoundationOne CDx assay. "That doesn't sound too controversial, right?" says Alain Borczuk, MD, vice chair of anatomic pathology and director of oncologic pathology, Northwell Health Cancer Institute. "It's not the only way in, but it's one of the ways in. If you're arguing for your patient that this is the biomarker that makes them eligible for the drug, then the next questions will be, What was the number? And what was the test?" And it's off to the races.



©2026 CAP TODAY, all rights reserved.

---

# As blood supply tightens, so too does mitigation

written by CAP TODAY  
September 19, 2022

September 2022—Picture a performer juggling tenpins while walking a high wire, knowing that a hurricane looms. Add a safety net that could disappear at any time. That's a sense of what hospital transfusion services experience in maintaining enough blood products to meet patients' needs.



©2026 CAP TODAY, all rights reserved.

---

## **BNP and NT-proBNP: how they differ, what it means**

written by CAP TODAY  
September 19, 2022

September 2022—Which biomarker for heart failure should be used—BNP or NT-proBNP—and does it matter? That’s the question Christopher W. Farnsworth, PhD, set out to answer in his “hot topic” talk (one of a trio) at the AACC meeting in July.



©2026 CAP TODAY, all rights reserved.

---

## **New data on rapid rule-out using high-sensitivity cTnT**

written by CAP TODAY  
September 19, 2022

September 2022—A single high-sensitivity cardiac troponin T measurement below the limit of quantitation of 6 ng/L is a safe and rapid method to identify a substantial number of patients at low risk for acute myocardial injury and infarction, say the authors of a recently published study.



©2026 CAP TODAY, all rights reserved.

---

# What's required in '23 for predictive marker tests

written by CAP TODAY  
September 19, 2022

September 2022—Beginning next year, two additional predictive marker tests will require enrollment in proficiency testing (PT), but for any predictive marker using immunohistochemistry or in situ hybridization, only laboratories that perform both staining and interpretation must participate in CAP-accepted PT.



©2026 CAP TODAY, all rights reserved.

---

# Need a written policy or procedure? Look for icon

written by CAP TODAY  
September 19, 2022

September 2022—A new icon in the accreditation checklist edition to be released next month will make it easier to know if a written policy or procedure is needed for compliance with a requirement, and easier to inspect and be inspected.



©2026 CAP TODAY, all rights reserved.